London, UK – 8 February 2019: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, will be announcing its Preliminary Results for the year ended 31 December 2018 on Thursday 14 March 2019.
A briefing for analysts will be held at 12:00pm GMT on the day of results at 85 Gresham Street, London EC2V 7NQ. There will also be a live webcast with a Q&A session. The presentation and webcast details will be made available on the Group’s website at www.oxb.com. A replay of the presentation will be made available shortly afterwards.
Please contact Consilium Strategic Communications for further details.
- Ends -
For further information, please contact:
Oxford BioMedica plc:
Catherine Isted, Head of Corporate Development & IR
Sarah MacLeod, Head of Communications
Tel: +44 (0) 1865 954161
Tel: +44 (0) 1865 783016
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/
Nicholas Brown/Olivia Manser
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations and GC LabCell, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxb.com.